Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 7,089 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Cancer
Interventions: Eribulin Mesylate, Pembrolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Neurotoxicity, Pain, Breast Cancer
Interventions: D-cycloserine, Placebo; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Chicago, Illinois • Madison, Wisconsin

Conditions: Cancer
Interventions: management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Colorectal Cancer
Interventions: BenFin, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 16
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 13 more

Conditions: Hereditary Cancer
Interventions: Diagnostic test; Diagnostic Test
Lead sponsor: Myriad Genetic Laboratories, Inc.; Industry
Eligibility: 18 Years to 84 Years · Female only
Enrollment: 553 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Boynton Beach, Florida • Hyannis, Massachusetts + 1 more

Conditions: Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions: CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine; Drug
Lead sponsor: Cyteir Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 12 more

Conditions: Breast Cancer
Interventions: 5-Fluorouracil, Cyclophosphamide, Doxorubicin, Paclitaxel, Epirubicin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Afuresertib, Afuresertib/placebo; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more

Conditions: Breast Cancer, Chemotherapy-Related Cognitive Impairment
Interventions: Individualized Piano Keyboard Instruction; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: Letrozole, Ribociclib, Placebo; Drug
Lead sponsor: Qamar Khan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 13
States / cities: Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more

Conditions: Breast Cancer
Interventions: Music; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Endometrial Cancer, Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 15,595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Bilateral mastectomy with reconstruction; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer Survivor, Cancer Related Cognitive Difficulties, Sleep, Quality of Life
Interventions: Prolonged Nightly Fasting, Health Education Videos; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Neoplasms, Breast Diseases, Renal Neoplasm, Solid Tumors
Interventions: Entinostat, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC
Interventions: Part A: AZD8186 monotherapy, Part B: AZD8186 monotherapy, Part C1: Abiraterone acetate combination with AZD8186, Part D1: AZD2014 combination with AZD8186, Part D2 AZD2014 combination with AZD8186, Part C2: Abiraterone acetate combination with AZD8186; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 5
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more

Conditions: Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions: dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis; Drug · Biological · Procedure + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: Phlebotomy - Blood sampling for GP88 at MM, SOC Tissue biopsy; Other · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 417 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Glen Burnie, Maryland

Conditions: Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
Interventions: PM01183 + paclitaxel +/- bevacizumab; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Telephone Counseling & Navigation (TCN), Mailed Targeted Print (TP), Usual Care (UC); Behavioral · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 21 Years and older · Female only
Enrollment: 668 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Lymphedema, Breast Cancer
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Female Breast Carcinoma, Healthy Subject
Interventions: Questionnaire Administration, Telephone-Based Intervention; Other · Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Group Sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 21 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Miami, Florida

Search by objective public record fields.

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer

Combined Breast Cancer Risk Study

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

Music as a Perioperative Therapy in Breast Cancer Patients

Bone Mineral Density and Subsequent Cancer Risk

A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders

The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

AZD8186 First Time In Patient Ascending Dose Study

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project

Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2

Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography

Facilitating Adjustment in Low Income Black Women With Breast Cancer